Cystic fibrosis

Thorax

Volumn 56, Issue 3, 2001, Pages 237-241

  Robinson, P ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMILORIDE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA CAROTENE; BETA LACTAMASE INHIBITOR; DORNASE ALFA; FISH OIL; GLUTATHIONE; IBUPROFEN; LEUKOCYTE ELASTASE INHIBITOR; PENTOXIFYLLINE; PROTEGRIN; PROTEINASE INHIBITOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; STEROID; TOBRAMYCIN; TYLOXAPOL;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; CHILD; CHILDHOOD DISEASE; CYSTIC FIBROSIS; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALNUTRITION; NEWBORN SCREENING; ONSET AGE; PHYSIOTHERAPY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS AUREUS;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; GENE THERAPY; HUMANS; INFANT; INFANT NUTRITION PHYSIOLOGY; INFANT, NEWBORN; NEONATAL SCREENING; PHYSICAL THERAPY MODALITIES; TOBRAMYCIN;

EID: 0035091713     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.56.3.237     Document Type: Review

References (35)

1. Clinical outcomes of newborn screening for cystic fibrosis
2. Does neonatal screening influence spirometry at 9 years of age?
3. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis
4. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period
5. Fusidic acid and lincomycin therapy in staphylococcal infections in cystic fibrosis
6. A multicentric comparison of related pharmacologic features of cephalexin and dicloxacillin given for two months to young children with cystic fibrosis
7. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years
8. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonisation with Pseudomonas aeruginosa
9. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis
10. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
11. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
12. Pseudomonas cepacia colonisation in patients with cystic fibrosis: Risk factors and clinical outcome
13. Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients
14. + Burkholderia cepacia causing cystic fibrosis centre epidemics in North America and Britain
15. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995)
16. Resistant gram-negative infections, including cystic fibrosis
17. Short term effects of three chest physiotherapy regimens in patients hospitalized for pulmonary exacerbations of cystic fibrosis: A cross over randomized study
18. Immediate and long term effects of chest physiotherapy in patients with cystic fibrosis
19. Role of conventional physiotherapy in cystic fibrosis
20. Long-term comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis
21. Postural drainage in cystic fibrosis: Is there a link with gastrooesophageal reflux?
22. Holding the baby: Head downwards positioning for physiotherapy does not cause gastro-oesophageal reflux
23. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
24. A multicenter study of alternate-day prednisolone therapy in patients with cystic fibrosis
25. Effect of high-dose ibuprofen in patients with cystic fibrosis
26. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis
27. The effects of the inhaled corticosteroid budesonide in lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis
28. Randomized controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis
29. The use of antiinflammatory medications in cystic fibrosis
30. The CF gene: 10 years on
31. Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption
32. Cystic fibrosis mortality in England and Wales and in Victoria, Australia
33. Inferences for health provision from survival data in cystic fibrosis
34. Clinical outcome in relation to care in centers specializing in cystic fibrosis: Cross sectional study